REG - GlaxoSmithKline PLC - Director/PDMR Shareholding
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus a+++++nd Matching Awards.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.0000
32,596 (Deferred)
£0.0000
19,234 (Matching)
d)
Aggregated information
Aggregated volume Price
51,830
£0.0000
e)
Date of the transaction
2019-02-18
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 18 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£15.756
15,345 (Deferred)
£15.756
9,053 (Matching)
d)
Aggregated information
Aggregated volume Price
24,398
£15.756
e)
Date of the transaction
2019-02-18
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Connor
b)
Position/status
President, Global Vaccines
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.0000
11,073 (Deferred)
£0.0000
6,534 (Matching)
d)
Aggregated information
Aggregated volume Price
17,607
£0.0000
e)
Date of the transaction
2019-02-18
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R Connor
b)
Position/status
President, Global Vaccines
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 18 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£15.756
5,218 (Deferred)
£15.756
3,079 (Matching)
d)
Aggregated information
Aggregated volume Price
8,297
£15.756
e)
Date of the transaction
2019-02-18
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S Dingemans
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.0000
43,044 (Deferred)
£0.0000
25,398 (Matching)
d)
Aggregated information
Aggregated volume Price
68,442
£0.0000
e)
Date of the transaction
2019-02-18
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S Dingemans
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 18 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£15.716
20,263 (Deferred)
£15.716
11,955 (Matching)
d)
Aggregated information
Aggregated volume Price
32,218
£15.716
e)
Date of the transaction
2019-02-18
f)
Place of the transaction
London Stock Exchange (XLON)
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£0.0000
9,064 (Deferred)
£0.0000
5,349 (Matching)
d)
Aggregated information
Aggregated volume Price
14,413
£0.0000
e)
Date of the transaction
2019-02-18
f)
Place of the transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial Notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 18 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.
c)
Price(s) and volume(s)
Price(s)
Volume(s)
£15.7215
4,271 (Deferred)
£15.7215
2,521 (Matching)
d)
Aggregated information
Aggregated volume Price
6,792
£15.7215
e)
Date of the transaction
2019-02-18
f)
Place of the transaction
London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDDSHXKLFFKLFXBBD
Recent news on GSK
See all newsREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Transaction in Own Shares
Announcement